Author:
Buil-Bruna Núria,López-Picazo José-María,Moreno-Jiménez Marta,Martín-Algarra Salvador,Ribba Benjamin,Trocóniz Iñaki F.
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
2. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol. 2004;22(22):4442–5.
3. Villaruz LC, Socinski MA. The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement. Clin Cancer Res. 2013;19(10):2629–36.
4. Bender B, Schindler E, Friberg L. Population pharmacokinetic pharmacodynamic modelling in oncology: a tool for predicting clinical response. Br J Clin Pharmacol. 2013;18(2):e86.
5. Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G. Mechanism-based pharmacokinetic–pharmacodynamic modeling—a new classification of biomarkers. Pharm Res. 2005;22(9):1432–7.
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献